JP7158371B2 - 新規ボツリヌスニューロトキシンおよびその誘導体 - Google Patents

新規ボツリヌスニューロトキシンおよびその誘導体 Download PDF

Info

Publication number
JP7158371B2
JP7158371B2 JP2019500553A JP2019500553A JP7158371B2 JP 7158371 B2 JP7158371 B2 JP 7158371B2 JP 2019500553 A JP2019500553 A JP 2019500553A JP 2019500553 A JP2019500553 A JP 2019500553A JP 7158371 B2 JP7158371 B2 JP 7158371B2
Authority
JP
Japan
Prior art keywords
bont
seq
polypeptide
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019500553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528042A (ja
JP2019528042A5 (enExample
Inventor
ステンマルク，ポール
ドン，ミン
ヅァン，シーツァイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2019528042A publication Critical patent/JP2019528042A/ja
Publication of JP2019528042A5 publication Critical patent/JP2019528042A5/ja
Priority to JP2022076994A priority Critical patent/JP7402916B2/ja
Application granted granted Critical
Publication of JP7158371B2 publication Critical patent/JP7158371B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2019500553A 2016-07-08 2017-07-07 新規ボツリヌスニューロトキシンおよびその誘導体 Active JP7158371B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022076994A JP7402916B2 (ja) 2016-07-08 2022-05-09 新規ボツリヌスニューロトキシンおよびその誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662360239P 2016-07-08 2016-07-08
US62/360,239 2016-07-08
PCT/US2017/041255 WO2018009903A2 (en) 2016-07-08 2017-07-07 A novel botulinum neurotoxin and its derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022076994A Division JP7402916B2 (ja) 2016-07-08 2022-05-09 新規ボツリヌスニューロトキシンおよびその誘導体

Publications (3)

Publication Number Publication Date
JP2019528042A JP2019528042A (ja) 2019-10-10
JP2019528042A5 JP2019528042A5 (enExample) 2020-08-20
JP7158371B2 true JP7158371B2 (ja) 2022-10-21

Family

ID=59384231

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019500553A Active JP7158371B2 (ja) 2016-07-08 2017-07-07 新規ボツリヌスニューロトキシンおよびその誘導体
JP2022076994A Active JP7402916B2 (ja) 2016-07-08 2022-05-09 新規ボツリヌスニューロトキシンおよびその誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022076994A Active JP7402916B2 (ja) 2016-07-08 2022-05-09 新規ボツリヌスニューロトキシンおよびその誘導体

Country Status (21)

Country Link
US (2) US11286473B2 (enExample)
EP (2) EP4212545A1 (enExample)
JP (2) JP7158371B2 (enExample)
KR (1) KR102530925B1 (enExample)
CN (1) CN109803980B (enExample)
AU (2) AU2017292922B9 (enExample)
BR (1) BR112019000278A2 (enExample)
CA (1) CA3030155A1 (enExample)
DK (1) DK3481852T5 (enExample)
EA (1) EA201990229A1 (enExample)
ES (1) ES2939001T3 (enExample)
FI (1) FI3481852T3 (enExample)
HU (1) HUE061429T2 (enExample)
IL (2) IL263754B2 (enExample)
MX (1) MX2019000151A (enExample)
PL (1) PL3481852T3 (enExample)
PT (1) PT3481852T (enExample)
SG (2) SG11201811338VA (enExample)
UA (1) UA125965C2 (enExample)
WO (1) WO2018009903A2 (enExample)
ZA (1) ZA201900341B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6088438B2 (ja) 2010-12-22 2017-03-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 連続的定向進化
MX381995B (es) * 2012-11-21 2025-03-13 Ipsen Bioinnovation Ltd Métodos para la producción de polipéptidos procesados proteolíticamente.
WO2015134121A2 (en) 2014-01-20 2015-09-11 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
WO2016077052A2 (en) 2014-10-22 2016-05-19 President And Fellows Of Harvard College Evolution of proteases
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
ES2762951T3 (es) * 2015-04-24 2020-05-26 Consiglio Nazionale Ricerche Nuevo uso terapéutico de la neurotoxina botulínica serotipo A
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EA201892643A1 (ru) * 2016-05-16 2019-06-28 Президент Энд Феллоуз Оф Гарвард Колледж Способ очистки и активации ботулинического нейротоксина
PL3481852T3 (pl) 2016-07-08 2023-07-24 Children's Medical Center Corporation Nowa neurotoksyna botulinowa i jej pochodne
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11040090B2 (en) * 2016-12-08 2021-06-22 Prime Bio, Inc Botulinum neurotoxin compositions
WO2019010164A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College Evolution of trna synthetases
US12060553B2 (en) 2017-08-25 2024-08-13 President And Fellows Of Harvard College Evolution of BoNT peptidases
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
US12098169B2 (en) * 2017-09-29 2024-09-24 Children's Medical Center Corporation Enterococcus faecium neurotoxin (BoNT/EN) and derivatives thereof
KR20200115584A (ko) 2018-01-30 2020-10-07 칠드런'즈 메디컬 센터 코포레이션 바실루스 시스템을 이용한 보툴리눔 신경독소의 생산
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
GB201815817D0 (en) * 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
WO2020065338A1 (en) 2018-09-28 2020-04-02 Ipsen Biopharm Limited Cell-based clostridal neurotoxin assays
GB201815844D0 (en) 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
US20220220466A1 (en) * 2019-04-17 2022-07-14 Children's Medical Center Corporation Catalytically inactive botulinum neurotoxin-like toxins and uses thereof
GB201907016D0 (en) 2019-05-17 2019-07-03 Ipsen Biopharm Ltd Screening method to determine suitability for participation in a clinical trial
US20220259269A1 (en) * 2019-07-15 2022-08-18 President And Fellows Of Harvard College Evolved botulinum neurotoxins and uses thereof
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
CN110938150B (zh) * 2019-12-16 2021-08-31 中国人民解放军军事科学院军事医学研究院 E型肉毒毒素重组l-hn抗原的制备方法及其应用
KR102610179B1 (ko) * 2019-12-18 2023-12-05 엠브릭스 주식회사 보툴리눔 신경 독소의 안전한 제조 방법
WO2022140249A1 (en) * 2020-12-21 2022-06-30 Children's Medical Center Corporation Improved receptor-binding domain of botulinum neurotoxin a and uses thereof
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
CN113495106B (zh) * 2021-02-10 2023-08-25 中国人民解放军军事科学院军事医学研究院 样品检测方法
CN114957482B (zh) * 2021-02-26 2024-09-24 重庆誉颜制药有限公司 一种经修饰的神经毒素的单链多肽及其用途
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
US20240158773A1 (en) * 2021-03-15 2024-05-16 Children's Medical Center Cprporation Engineered botulinum neurotoxin a protease domain with improved efficacy
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
BR112023020057A2 (pt) 2021-03-30 2024-03-12 Ipsen Biopharm Ltd Tratamento de dor e distúrbios inflamatórios
CA3211472A1 (en) 2021-03-30 2022-10-06 Mikhail KALINICHEV Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
WO2022228443A1 (en) * 2021-04-26 2022-11-03 Shanghaitech University Intramuscular compositions of botulinum neurotoxins
AU2022321126A1 (en) * 2021-08-06 2024-02-29 Kao Corporation Nucleic acid structure utilizing snare
KR20240116485A (ko) 2021-11-22 2024-07-29 입센 바이오팜 리미티드 통증의 치료
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202206361D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206348D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202206362D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202206353D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
WO2023239229A1 (ko) * 2022-06-10 2023-12-14 (주)메디톡스 보툴리눔 독소 안정화 조성물, 이를 포함하는 보툴리눔 독소 제제 및 이에 사용하기 위한 폴리펩티드
CN115785237B (zh) * 2022-09-01 2023-06-16 上海蓝晶生物科技有限公司 一种重组肉毒杆菌毒素及其制备方法
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
KR20250069883A (ko) 2022-09-30 2025-05-20 입센 바이오팜 리미티드 방광 통증 증후군 치료에 사용되는 클로스트리디움 신경독소
GB202307439D0 (en) 2023-05-18 2023-07-05 Ipsen Biopharm Ltd Treatment of a headache disorder with botylinum neurotoxin a
CN116813727B (zh) * 2023-06-08 2025-06-06 苏州德进生物制药有限公司 一种a型肉毒毒素的制备方法及其应用
WO2025093845A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
WO2025093844A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation
GB202320108D0 (en) 2023-12-28 2024-02-14 Ipsen Biopharm Ltd Biosensor
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay
CN118388606B (zh) * 2024-04-25 2025-09-23 武汉大学 一种结合蛋白Bntifitin及其在制备用于治疗冠状病毒感染的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014854A1 (en) 2007-07-26 2009-01-29 Allergan, Inc. Methods of activiting clostridial toxins
WO2012041761A2 (en) 2010-09-28 2012-04-05 Merz Pharma Gmbh & Co. Kgaa Botulinum neurotoxin polypeptides exhibiting a prolonged activity
JP2015519362A (ja) 2012-05-30 2015-07-09 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたボツリヌス神経毒素

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
DE69526340T2 (de) 1994-05-09 2002-11-14 William J. Binder Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
EP2502930B1 (en) * 2003-12-19 2016-06-29 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
WO2007094754A2 (en) * 2005-01-27 2007-08-23 The Regents Of The University Of Califordnia Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
CA2601592A1 (en) * 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
AU2007347781B2 (en) * 2006-07-11 2013-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
CN100577149C (zh) * 2006-12-21 2010-01-06 北京民海生物科技有限公司 一种治疗用a型肉毒毒素冻干粉针剂新型冻干保护剂配方
CA2784666A1 (en) * 2009-12-16 2011-11-17 Allergan, Inc. Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
JP6148979B2 (ja) * 2010-05-20 2017-06-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 分解性クロストリジウム毒素
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
DK3242884T3 (da) * 2015-01-09 2021-04-19 Ipsen Bioinnovation Ltd Kationiske neurotoksiner
CN115925835A (zh) * 2015-03-26 2023-04-07 哈佛大学校长及研究员协会 工程改造的肉毒杆菌神经毒素
GB201505306D0 (en) * 2015-03-27 2015-05-13 Ipsen Biopharm Ltd Chimeric polypeptides
AU2016310521A1 (en) * 2015-08-27 2018-03-01 Massachusetts Institute Of Technology Compositions and methods for treatment of pain
KR20190025906A (ko) * 2016-06-08 2019-03-12 칠드런'즈 메디컬 센터 코포레이션 조작된 보툴리눔 신경독소
PL3481852T3 (pl) 2016-07-08 2023-07-24 Children's Medical Center Corporation Nowa neurotoksyna botulinowa i jej pochodne
US11117935B2 (en) * 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
EP3312290A1 (en) * 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
EP3529371B1 (en) * 2016-10-21 2022-06-22 Toxogen GmbH A functional detection assay devoid of antibodies for serotyping of botulinum neurotoxins
US20190364907A1 (en) 2017-07-21 2019-12-05 The Regents Of The University Of California Compositions of mosquitocidal clostridial proteins and methods of use
US12098169B2 (en) * 2017-09-29 2024-09-24 Children's Medical Center Corporation Enterococcus faecium neurotoxin (BoNT/EN) and derivatives thereof
KR20200115584A (ko) * 2018-01-30 2020-10-07 칠드런'즈 메디컬 센터 코포레이션 바실루스 시스템을 이용한 보툴리눔 신경독소의 생산
WO2019243376A1 (en) * 2018-06-18 2019-12-26 Ipsen Biopharm Limited Intramuscular injection of botulinum toxin for the treatment of vulvodynia
WO2020065338A1 (en) * 2018-09-28 2020-04-02 Ipsen Biopharm Limited Cell-based clostridal neurotoxin assays
GB201815817D0 (en) * 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014854A1 (en) 2007-07-26 2009-01-29 Allergan, Inc. Methods of activiting clostridial toxins
WO2012041761A2 (en) 2010-09-28 2012-04-05 Merz Pharma Gmbh & Co. Kgaa Botulinum neurotoxin polypeptides exhibiting a prolonged activity
JP2015519362A (ja) 2012-05-30 2015-07-09 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたボツリヌス神経毒素

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clostridium botulinum DNA, complete genome, strain: 111，GenBank: AP014696.1，2015年02月21日，https://www.ncbi.nlm.nih.gov/nuccore/AP014696.1
putative botulinum neurotoxin [Clostridium botulinum]，GenBank: BAQ12790.1，2015年02月21日，https://www.ncbi.nlm.nih.gov/protein/BAQ12790

Also Published As

Publication number Publication date
IL298102A (en) 2023-01-01
JP2019528042A (ja) 2019-10-10
JP2022119794A (ja) 2022-08-17
IL263754B2 (en) 2023-04-01
IL298102B1 (en) 2025-05-01
WO2018009903A3 (en) 2018-02-15
JP7402916B2 (ja) 2023-12-21
EP3481852A2 (en) 2019-05-15
BR112019000278A2 (pt) 2019-04-24
PT3481852T (pt) 2023-02-22
KR102530925B1 (ko) 2023-05-11
US20200224185A9 (en) 2020-07-16
DK3481852T5 (da) 2024-09-02
IL263754B (en) 2022-12-01
AU2022203264A1 (en) 2022-06-02
KR20190026834A (ko) 2019-03-13
UA125965C2 (uk) 2022-07-20
FI3481852T3 (fi) 2023-03-19
AU2022203264B2 (en) 2024-02-22
DK3481852T3 (da) 2023-02-27
EP3481852B1 (en) 2022-12-07
US11286473B2 (en) 2022-03-29
CN109803980B (zh) 2023-07-25
CA3030155A1 (en) 2018-01-11
EP4212545A1 (en) 2023-07-19
MX2019000151A (es) 2019-08-29
SG10201912102WA (en) 2020-02-27
ES2939001T3 (es) 2023-04-18
EA201990229A1 (ru) 2019-06-28
AU2017292922A1 (en) 2019-01-31
ZA201900341B (en) 2023-07-26
WO2018009903A2 (en) 2018-01-11
IL263754A (en) 2019-01-31
HUE061429T2 (hu) 2023-06-28
US20220177867A1 (en) 2022-06-09
SG11201811338VA (en) 2019-01-30
IL298102B2 (en) 2025-09-01
AU2017292922B9 (en) 2022-05-12
CN109803980A (zh) 2019-05-24
AU2017292922B2 (en) 2022-02-17
PL3481852T3 (pl) 2023-07-24
US20190136216A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
JP7402916B2 (ja) 新規ボツリヌスニューロトキシンおよびその誘導体
US12098169B2 (en) Enterococcus faecium neurotoxin (BoNT/EN) and derivatives thereof
US11104891B2 (en) Engineered botulinum neurotoxins
US20240158773A1 (en) Engineered botulinum neurotoxin a protease domain with improved efficacy
HK40008476B (en) A novel botulinum neurotoxin and its derivatives
HK40008476A (en) A novel botulinum neurotoxin and its derivatives
US20240082369A1 (en) Improved receptor-binding domain of botulinum neurotoxin a and uses thereof
EA041568B1 (ru) Новый ботулинический нейротоксин и его производные
WO2024073664A2 (en) Modified bont/a2 receptor-binding domains

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200707

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211014

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220509

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220517

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220614

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221011

R150 Certificate of patent or registration of utility model

Ref document number: 7158371

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250